메뉴 건너뛰기




Volumn 26, Issue 6, 2003, Pages 421-430

The Role of Estrogens in BRCA1/2 Mutation Carriers: Reflections on the Past, Issues for the Future

Author keywords

BRCA1 2; Estrogen; Hereditary cancer; Oophorectomy; Prophylactic; Prophylactic mastectomy; Syndrome

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

EID: 0346120207     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (2)

References (70)
  • 1
    • 0030893779 scopus 로고    scopus 로고
    • Recommendations for follow-up care of individuals with an inherited predisposition to cancer. 2, BRCA1, BRCA2
    • Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. 2, BRCA1, BRCA2. JAMA. 1997;277:997-1003.
    • (1997) JAMA , vol.277 , pp. 997-1003
    • Burke, W.1    Daly, M.2    Garber, J.3
  • 2
    • 0037878019 scopus 로고    scopus 로고
    • Best clinical practices
    • Executive Committee and Panel, ed. Rockville, Md: US Dept of Health and Human Services
    • Executive Committee and Panel. Best clinical practices. In: Executive Committee and Panel, ed. Women's Health and Menopause: A Comprehensive Approach. Rockville, Md: US Dept of Health and Human Services; 2002:1-28.
    • (2002) Women's Health and Menopause: A Comprehensive Approach , pp. 1-28
  • 3
    • 0032528265 scopus 로고    scopus 로고
    • The concise handbook of family cancer syndromes
    • Lindor N, Greene M, for the Mayo Familial Cancer Program. The concise handbook of family cancer syndromes. J Natl Cancer Inst. 1998; 90:1039-1071.
    • (1998) J Natl Cancer Inst , vol.90 , pp. 1039-1071
    • Lindor, N.1    Greene, M.2
  • 4
    • 0012742799 scopus 로고    scopus 로고
    • Atlanta, Ga: American Cancer Society Inc.
    • American Cancer Society. Cancer Facts & Figures 2003. Atlanta, Ga: American Cancer Society Inc; 2003.
    • (2003) Cancer Facts & Figures 2003
  • 6
    • 0038744296 scopus 로고    scopus 로고
    • Average risk of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected incase series unselected for family history: A combined analysis of 22 studies
    • Antoniou A, Pharoh P, Narod S, et al. Average risk of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected incase series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
    • (2003) Am J Hum Genet , vol.72 , pp. 1117-1130
    • Antoniou, A.1    Pharoh, P.2    Narod, S.3
  • 7
    • 0031832541 scopus 로고    scopus 로고
    • Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk
    • Frank T, Manley S, Olopade O, Cummings S, Garber J. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998;16(7):2417-2425.
    • (1998) J Clin Oncol , vol.16 , Issue.7 , pp. 2417-2425
    • Frank, T.1    Manley, S.2    Olopade, O.3    Cummings, S.4    Garber, J.5
  • 8
    • 0033610723 scopus 로고    scopus 로고
    • Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2
    • Jernstrom H, Lerman C, Ghadirian P, et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999;354(9193): 1846-1850.
    • (1999) Lancet , vol.354 , Issue.9193 , pp. 1846-1850
    • Jernstrom, H.1    Lerman, C.2    Ghadirian, P.3
  • 9
    • 0033668796 scopus 로고    scopus 로고
    • Progestins and menopause: Epidemiological studies of risks of endometrial and breast cancer
    • Pike M, Ross R. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids. 2000;65:659-664.
    • (2000) Steroids , vol.65 , pp. 659-664
    • Pike, M.1    Ross, R.2
  • 10
    • 0029056755 scopus 로고
    • The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
    • Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332(24):1589-1593.
    • (1995) N Engl J Med , vol.332 , Issue.24 , pp. 1589-1593
    • Colditz, G.A.1    Hankinson, S.E.2    Hunter, D.J.3
  • 11
    • 0032547326 scopus 로고    scopus 로고
    • Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
    • Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
    • (1998) JAMA , vol.280 , pp. 605-613
    • Hulley, S.1    Grady, D.2    Bush, T.3
  • 12
    • 0034640040 scopus 로고    scopus 로고
    • Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
    • Shilpak MG, Grady D, Bush T, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283:1845-1852.
    • (2000) JAMA , vol.283 , pp. 1845-1852
    • Shilpak, M.G.1    Grady, D.2    Bush, T.3
  • 13
    • 0037014584 scopus 로고    scopus 로고
    • Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II)
    • Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:49-57.
    • (2002) JAMA , vol.288 , pp. 49-57
    • Grady, D.1    Herrington, D.2    Bittner, V.3
  • 14
    • 0037014630 scopus 로고    scopus 로고
    • Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II)
    • Hulley S, Fulberg C, Barrett Connor E, et al, for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:58-66.
    • (2002) JAMA , vol.288 , pp. 58-66
    • Hulley, S.1    Fulberg, C.2    Barrett Connor, E.3
  • 15
    • 0037125379 scopus 로고    scopus 로고
    • Risks and benefits of estrogen plus progestin in healthy postmenopausal women
    • Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321-333.
    • (2002) JAMA , vol.288 , Issue.3 , pp. 321-333
  • 16
    • 0036569877 scopus 로고    scopus 로고
    • The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2
    • Lakhani S, van der Vijver MJ, Jacqueneir J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9): 2310-2318.
    • (2002) J Clin Oncol , vol.20 , Issue.9 , pp. 2310-2318
    • Lakhani, S.1    Van Der Vijver, M.J.2    Jacqueneir, J.3
  • 17
    • 0035219808 scopus 로고    scopus 로고
    • Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: Computed efficacy, effectiveness and impact
    • Eisinger F, Charafe-Jauffret E, Jacqueneir J, et al. Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact. Int J Oncol. 2001;18:5-10.
    • (2001) Int J Oncol , vol.18 , pp. 5-10
    • Eisinger, F.1    Charafe-Jauffret, E.2    Jacqueneir, J.3
  • 18
    • 0035861037 scopus 로고    scopus 로고
    • Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2
    • King M, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA. 2001;286(18): 2251-2256.
    • (2001) JAMA , vol.286 , Issue.18 , pp. 2251-2256
    • King, M.1
  • 19
    • 0034329366 scopus 로고    scopus 로고
    • Are BRCA1 and BRCA2 associated breast cancers different? Prognosis of BRCA1 associated breast cancer
    • Robson M. Are BRCA1 and BRCA2 associated breast cancers different? Prognosis of BRCA1 associated breast cancer. J Clin Oncol. 2000; 18(21S):113S-118S.
    • (2000) J Clin Oncol , vol.18 , Issue.21 S
    • Robson, M.1
  • 20
    • 0034331177 scopus 로고    scopus 로고
    • Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients
    • Verhoog L, Berns E, Brekelmans C, et al. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol. 2000;18(21S):119S-124S.
    • (2000) J Clin Oncol , vol.18 , Issue.21 S
    • Verhoog, L.1    Berns, E.2    Brekelmans, C.3
  • 21
    • 0037148435 scopus 로고    scopus 로고
    • Estimates of the likely prophylactic effect of tamoxifen in women with high-risk BRCA1 and BRCA2 mutations
    • Duffy SW, Nixon RM. Estimates of the likely prophylactic effect of tamoxifen in women with high-risk BRCA1 and BRCA2 mutations. Br J Cancer. 2002;86:218-221.
    • (2002) Br J Cancer , vol.86 , pp. 218-221
    • Duffy, S.W.1    Nixon, R.M.2
  • 22
    • 0034597916 scopus 로고    scopus 로고
    • Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study
    • Narod S, Brunet J, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet. 2000;356:1876-1881.
    • (2000) Lancet , vol.356 , pp. 1876-1881
    • Narod, S.1    Brunet, J.2    Ghadirian, P.3
  • 23
    • 0034331054 scopus 로고    scopus 로고
    • Chemoprevention options for BRCA1 and BRCA2 mutation carriers
    • Eeles R, Powles T. Chemoprevention options for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2000;18(21S):93S-99S.
    • (2000) J Clin Oncol , vol.18 , Issue.21 S
    • Eeles, R.1    Powles, T.2
  • 24
    • 0032514413 scopus 로고    scopus 로고
    • Oral contraceptives and the risk of hereditary ovarian cancer
    • Narod S, Risch H, Moslehr R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 1998;339(7):424-428.
    • (1998) N Engl J Med , vol.339 , Issue.7 , pp. 424-428
    • Narod, S.1    Risch, H.2    Moslehr, R.3
  • 25
    • 0033768040 scopus 로고    scopus 로고
    • Health benefits of oral contraceptives
    • Jensen J, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am. 2000;27(4):705-721.
    • (2000) Obstet Gynecol Clin North Am , vol.27 , Issue.4 , pp. 705-721
    • Jensen, J.1    Speroff, L.2
  • 26
    • 0034255545 scopus 로고    scopus 로고
    • Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives
    • Ness R, Grisso J, Klapper J. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol. 2000;152(3):233-241.
    • (2000) Am J Epidemiol , vol.152 , Issue.3 , pp. 233-241
    • Ness, R.1    Grisso, J.2    Klapper, J.3
  • 27
    • 0035954651 scopus 로고    scopus 로고
    • Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation
    • Modan B, Hartage P, Hirsch-Vechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. New Engl J Med. 2001;345(4):235-240.
    • (2001) New Engl J Med , vol.345 , Issue.4 , pp. 235-240
    • Modan, B.1    Hartage, P.2    Hirsch-Vechezkel, G.3
  • 28
    • 0035849283 scopus 로고    scopus 로고
    • Tubal ligation and risk of ovarian cancer in carriers for BRCA1 or BRCA2 mutations: A case control study
    • Narod S, Ping S, Sun P, et al. Tubal ligation and risk of ovarian cancer in carriers for BRCA1 or BRCA2 mutations: a case control study. Lancet. 2001;357:1467-1470.
    • (2001) Lancet , vol.357 , pp. 1467-1470
    • Narod, S.1    Ping, S.2    Sun, P.3
  • 29
    • 0034638446 scopus 로고    scopus 로고
    • Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer
    • Gabrick D, Hartmann L, Cerhan J, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA. 2000;284(14):1791-1798.
    • (2000) JAMA , vol.284 , Issue.14 , pp. 1791-1798
    • Gabrick, D.1    Hartmann, L.2    Cerhan, J.3
  • 30
    • 0030865837 scopus 로고    scopus 로고
    • Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
    • Ursin G, Henderson B, Haile R, et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res. 1997;57:3678-3681.
    • (1997) Cancer Res , vol.57 , pp. 3678-3681
    • Ursin, G.1    Henderson, B.2    Haile, R.3
  • 31
    • 0037021659 scopus 로고    scopus 로고
    • Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    • Narod S, Dube M, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. JNCI. 2002;94(23): 1773-1779.
    • (2002) JNCI , vol.94 , Issue.23 , pp. 1773-1779
    • Narod, S.1    Dube, M.2    Klijn, J.3
  • 32
    • 0019960002 scopus 로고
    • Intraabdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families
    • Tobacman J, Tucker M, Kase R, Greene M, Costa J, Fraumeni J. Intraabdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet. 1982;2:795-797.
    • (1982) Lancet , vol.2 , pp. 795-797
    • Tobacman, J.1    Tucker, M.2    Kase, R.3    Greene, M.4    Costa, J.5    Fraumeni, J.6
  • 33
    • 0027483251 scopus 로고
    • Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer
    • Piver M, Jishi M, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. Cancer. 1993;71:2751-2755.
    • (1993) Cancer , vol.71 , pp. 2751-2755
    • Piver, M.1    Jishi, M.2    Tsukada, Y.3    Nava, G.4
  • 35
    • 0001771124 scopus 로고    scopus 로고
    • Ovarian cancer risk reduction after Bilateral Prophylactic Oophorectomy (BPO) in BRCA1 and BRCA2 mutation carriers
    • Weber B, Punzalan C, Eisen A, et al. Ovarian cancer risk reduction after Bilateral Prophylactic Oophorectomy (BPO) in BRCA1 and BRCA2 mutation carriers [abstract]. Am Soc Hum Genet. 2000;251:59.
    • (2000) Am Soc Hum Genet , vol.251 , pp. 59
    • Weber, B.1    Punzalan, C.2    Eisen, A.3
  • 36
    • 0031938628 scopus 로고    scopus 로고
    • Prophylactic oophorectomy in colorectal carcinoma: Preliminary results of a randomized trial
    • Young-Fadok T, Wolff B, Nivatvongs S, Metzger P, Ilstrup D. Prophylactic oophorectomy in colorectal carcinoma: preliminary results of a randomized trial. Dis Colon Rectum. 1998;41(3):277-285.
    • (1998) Dis Colon Rectum , vol.41 , Issue.3 , pp. 277-285
    • Young-Fadok, T.1    Wolff, B.2    Nivatvongs, S.3    Metzger, P.4    Ilstrup, D.5
  • 37
    • 0037162115 scopus 로고    scopus 로고
    • Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
    • Kauff N, Satagopan J, Bobson M, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New Engl J Med. 2002;346(21):1609-1615.
    • (2002) New Engl J Med , vol.346 , Issue.21 , pp. 1609-1615
    • Kauff, N.1    Satagopan, J.2    Bobson, M.3
  • 38
    • 0037162110 scopus 로고    scopus 로고
    • Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations
    • Rebbeck T, Lynch H, Neuhausen S, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New Engl J Med. 2002;346(21): 1616-1622.
    • (2002) New Engl J Med , vol.346 , Issue.21 , pp. 1616-1622
    • Rebbeck, T.1    Lynch, H.2    Neuhausen, S.3
  • 39
    • 0028801693 scopus 로고
    • Ovarian cancer: Screening, treatment, and follow-up
    • NCI Consensus Conference/NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment, and follow-up. JAMA. 1995;273(6):491-497.
    • (1995) JAMA , vol.273 , Issue.6 , pp. 491-497
  • 40
    • 0032478961 scopus 로고    scopus 로고
    • Primary peritoneal carcinoma can have multifocal origins: Implications for prophylactic oophorectomy
    • Eisen A, Weber B. Primary peritoneal carcinoma can have multifocal origins: implications for prophylactic oophorectomy. J Natl Cancer Inst. 1998;90(11):797-799.
    • (1998) J Natl Cancer Inst , vol.90 , Issue.11 , pp. 797-799
    • Eisen, A.1    Weber, B.2
  • 41
    • 0027074247 scopus 로고
    • Papillary peritoneal carcinomatosis after prophylactic oophorectomy
    • Kemp G, Hsiu J, Andrews M. Papillary peritoneal carcinomatosis after prophylactic oophorectomy. Gynecol Oncol. 1992;47:395-397.
    • (1992) Gynecol Oncol , vol.47 , pp. 395-397
    • Kemp, G.1    Hsiu, J.2    Andrews, M.3
  • 42
    • 0033942547 scopus 로고    scopus 로고
    • Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy
    • Lu K, Garber J, Cramet D, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 2000;18(14):2728-2732.
    • (2000) J Clin Oncol , vol.18 , Issue.14 , pp. 2728-2732
    • Lu, K.1    Garber, J.2    Cramet, D.3
  • 43
    • 0033944968 scopus 로고    scopus 로고
    • Prophylactic oophorectomy: Clinical considerations
    • Gotlieb W, Baruch G, Friedman E. Prophylactic oophorectomy: clinical considerations. Semin Surg Oncol. 2000;19:20-27.
    • (2000) Semin Surg Oncol , vol.19 , pp. 20-27
    • Gotlieb, W.1    Baruch, G.2    Friedman, E.3
  • 44
    • 0031817420 scopus 로고    scopus 로고
    • Prophylactic oophorectomy: A continuing controversy
    • Fong Y, Lim F, Arulkumaran S. Prophylactic oophorectomy: a continuing controversy. Obstet Gynecol Surv. 1998;53(8):493-498.
    • (1998) Obstet Gynecol Surv , vol.53 , Issue.8 , pp. 493-498
    • Fong, Y.1    Lim, F.2    Arulkumaran, S.3
  • 45
    • 0033199603 scopus 로고    scopus 로고
    • Bad news/good news: Information about breast cancer risk following prophylactic oophorectomy
    • Helzlsouer K. Bad news/good news: information about breast cancer risk following prophylactic oophorectomy. J Natl Cancer Inst. 1999;91(17): 1442-1443.
    • (1999) J Natl Cancer Inst , vol.91 , Issue.17 , pp. 1442-1443
    • Helzlsouer, K.1
  • 46
    • 0033408439 scopus 로고    scopus 로고
    • Managing hereditary ovarian cancer risk
    • Berchuck A, Schildkraut J, Marks J, Futreal P. Managing hereditary ovarian cancer risk. Cancer. 1999;86(11):2517-2524.
    • (1999) Cancer , vol.86 , Issue.11 , pp. 2517-2524
    • Berchuck, A.1    Schildkraut, J.2    Marks, J.3    Futreal, P.4
  • 47
    • 0033199926 scopus 로고    scopus 로고
    • Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
    • Rebbeck T, Levin A, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91(17):1475-1479.
    • (1999) J Natl Cancer Inst , vol.91 , Issue.17 , pp. 1475-1479
    • Rebbeck, T.1    Levin, A.2    Eisen, A.3
  • 48
    • 0034331055 scopus 로고    scopus 로고
    • Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
    • Rebbeck T. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2000;18(21s):100s-103s.
    • (2000) J Clin Oncol , vol.18 , Issue.21 S
    • Rebbeck, T.1
  • 49
    • 0035819530 scopus 로고    scopus 로고
    • Prophylactic oophorectomy in the genome age: Balancing new data against uncertainties
    • Newman L. Prophylactic oophorectomy in the genome age: balancing new data against uncertainties. J Natl Cancer Inst. 2001;93(3):173-175.
    • (2001) J Natl Cancer Inst , vol.93 , Issue.3 , pp. 173-175
    • Newman, L.1
  • 50
    • 0030590570 scopus 로고    scopus 로고
    • Prophylactic cancer surgeries offer no guarantees, uncertain outcomes
    • Holzman D. Prophylactic cancer surgeries offer no guarantees, uncertain outcomes. J Natl Cancer Inst. 1996;88(20):1428-1427.
    • (1996) J Natl Cancer Inst , vol.88 , Issue.20 , pp. 1428-1427
    • Holzman, D.1
  • 51
    • 0037093059 scopus 로고    scopus 로고
    • Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: An updated decision analysis
    • Grann V, Jacobson J, Thomason D, Hershman D, Heitjan D, Neugut A. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol. 2002;20(10):2520-2529.
    • (2002) J Clin Oncol , vol.20 , Issue.10 , pp. 2520-2529
    • Grann, V.1    Jacobson, J.2    Thomason, D.3    Hershman, D.4    Heitjan, D.5    Neugut, A.6
  • 52
    • 0033452876 scopus 로고    scopus 로고
    • Prophylactic mastectomy and inherited predisposition to breast cancer
    • Hughes K, Papa M, Whitney T, McLellan R. Prophylactic mastectomy and inherited predisposition to breast cancer. Cancer. 1999;86(11): 2502-2516.
    • (1999) Cancer , vol.86 , Issue.11 , pp. 2502-2516
    • Hughes, K.1    Papa, M.2    Whitney, T.3    McLellan, R.4
  • 53
    • 0033552904 scopus 로고    scopus 로고
    • Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
    • Hartmann L, Schaid D, Woods J, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77-84.
    • (1999) N Engl J Med , vol.340 , Issue.2 , pp. 77-84
    • Hartmann, L.1    Schaid, D.2    Woods, J.3
  • 54
    • 0034101299 scopus 로고    scopus 로고
    • Prophylactic mastectomy: Evolving perspectives
    • Sakorafas G, Tsiotou A. Prophylactic mastectomy: evolving perspectives. Eur J Cancer. 2000;36:567-578.
    • (2000) Eur J Cancer , vol.36 , pp. 567-578
    • Sakorafas, G.1    Tsiotou, A.2
  • 55
    • 0034691671 scopus 로고    scopus 로고
    • Reducing the risk of breast cancer
    • Chlebowski R. Reducing the risk of breast cancer. N Engl J Med. 2000; 343(3):191-198.
    • (2000) N Engl J Med , vol.343 , Issue.3 , pp. 191-198
    • Chlebowski, R.1
  • 56
    • 0034042020 scopus 로고    scopus 로고
    • Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer
    • Kuschel B, Lux M, Goecke T, Beckmann M. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. Eur J Cancer Prev. 2000;9:139-150.
    • (2000) Eur J Cancer Prev , vol.9 , pp. 139-150
    • Kuschel, B.1    Lux, M.2    Goecke, T.3    Beckmann, M.4
  • 57
    • 0035478195 scopus 로고    scopus 로고
    • Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer
    • McDonnell S, Schaid D, Myers J, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19(19):3938-3943.
    • (2001) J Clin Oncol , vol.19 , Issue.19 , pp. 3938-3943
    • McDonnell, S.1    Schaid, D.2    Myers, J.3
  • 58
    • 0035913275 scopus 로고    scopus 로고
    • Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation
    • Meijers-Heijboer H, Van Geel B, Van Putten W, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159-164.
    • (2001) N Engl J Med , vol.345 , Issue.3 , pp. 159-164
    • Meijers-Heijboer, H.1    Van Geel, B.2    Van Putten, W.3
  • 59
    • 0035913276 scopus 로고    scopus 로고
    • Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations-facts and controversy
    • Eisen A, Weber B. Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations-facts and controversy. N Engl J Med. 2001; 345(3):207-208.
    • (2001) N Engl J Med , vol.345 , Issue.3 , pp. 207-208
    • Eisen, A.1    Weber, B.2
  • 60
    • 0347249941 scopus 로고    scopus 로고
    • Position statement on prophylactic mastectomy
    • Society of Surgical Oncology. 2001. Position statement on prophylactic mastectomy. Society Surg Oncol. Available at www.surgonc.org. Accessed August 2001.
    • (2001) Society Surg Oncol
  • 61
    • 0030909527 scopus 로고    scopus 로고
    • Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations
    • Schrag D, Kuntz K, Garber J, Weeks J. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997; 336(20):1465-1471.
    • (1997) N Engl J Med , vol.336 , Issue.20 , pp. 1465-1471
    • Schrag, D.1    Kuntz, K.2    Garber, J.3    Weeks, J.4
  • 62
    • 0034124104 scopus 로고    scopus 로고
    • Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery
    • Kuerer H, Hwang S, Anthony J, et al. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. Ann Surg Oncol. 2000;7(5):325-332.
    • (2000) Ann Surg Oncol , vol.7 , Issue.5 , pp. 325-332
    • Kuerer, H.1    Hwang, S.2    Anthony, J.3
  • 63
    • 0001259749 scopus 로고    scopus 로고
    • NCCN practice guidelines: Genetics/familial high-risk cancer screenings
    • Daly M. NCCN practice guidelines: genetics/familial high-risk cancer screenings. Oncology. 1999;13(11A):161-183.
    • (1999) Oncology , vol.13 , Issue.11 A , pp. 161-183
    • Daly, M.1
  • 66
    • 0034090866 scopus 로고    scopus 로고
    • The management of women at high risk of experiencing hereditary breast and ovarian cancer. The Lahey guidelines
    • Hughes K, Roche C, Whitney T, McLellan R. The management of women at high risk of experiencing hereditary breast and ovarian cancer. The Lahey guidelines. Dis Manage Health Outcomes. 2000;7(4):201-215.
    • (2000) Dis Manage Health Outcomes , vol.7 , Issue.4 , pp. 201-215
    • Hughes, K.1    Roche, C.2    Whitney, T.3    McLellan, R.4
  • 67
    • 0038715898 scopus 로고    scopus 로고
    • American Cancer Society guidelines for the breast cancer screening: Update 2003
    • Smith R, Saslow D, Sawyer K, et al. American Cancer Society guidelines for the breast cancer screening: update 2003. CA Cancer J Clin. 2003;53(3):141-169.
    • (2003) CA Cancer J Clin , vol.53 , Issue.3 , pp. 141-169
    • Smith, R.1    Saslow, D.2    Sawyer, K.3
  • 68
    • 0038501057 scopus 로고    scopus 로고
    • American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility
    • American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21(12):1-10.
    • (2003) J Clin Oncol , vol.21 , Issue.12 , pp. 1-10
  • 69
    • 0029926091 scopus 로고    scopus 로고
    • Tamoxifen and endometrial cancer
    • American College of Obstetrics and Gynecologists Committee on Gynecologic Practice. Tamoxifen and endometrial cancer. Int J Gynecol Obstet. 1996;53:197-199.
    • (1996) Int J Gynecol Obstet , vol.53 , pp. 197-199


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.